Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
Saved in:
| Title: | Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting |
|---|---|
| Authors: | Fulgent Genetics, Inc. |
| Source: | Business Wire (English). 04/22/2026. |
| Abstract: | Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. [ABSTRACT FROM PUBLISHER] |
|---|
